Home › Funds › Artia Global Partners LP › SYRE
Artia Global Partners LP position in SYRE
SPYRE THERAPEUTICS INC · Health Care
Artia Global Partners LP reported holding 4,000 shares of SYRE (SPYRE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$356K, representing 0.07% of its reported portfolio and ranking #49 among its reported holdings. Artia Global Partners LP has disclosed SYRE holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Artia Global Partners LP's SYRE position evolved
Artia Global Partners LP first disclosed a stake in SYRE in Q2 2026 at 4,000 shares (US$355K). The position peaked in Q3 2026 at 4,000 shares, worth US$356K. Across 2 filings, Artia Global Partners LP held the position steady without any share-count change. The most recent filing (Q3 2026) shows 4,000 shares valued at US$356K.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 4.00K | $355.12K | New |
| Q3 2026 | 4.00K | $356.12K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SYRE and 13F data
SYRE (SPYRE THERAPEUTICS INC) is a Health Care company. 65 other funds we track also report a position in SYRE — the largest reported positions include Paradigm Biocapital Advisors LP (US$396.8M), PERCEPTIVE ADVISORS LLC (US$383.5M), RTW INVESTMENTS, LP (US$328.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SYRE
- Paradigm Biocapital Advisors LP 4.46M sh · $396.85M · Q3 2026
- PERCEPTIVE ADVISORS LLC 4.32M sh · $383.48M · Q2 2026
- RTW INVESTMENTS, LP 3.69M sh · $328.68M · Q3 2026
- Venrock Adviser, LLC 2.99M sh · $265.05M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 2.76M sh · $245.76M · Q3 2026
- TCG Crossover Management, LLC 1.90M sh · $169.21M · Q3 2026
- TANG CAPITAL MANAGEMENT LLC 1.89M sh · $167.99M · Q2 2026
- Affinity Asset Advisors, LLC 1.28M sh · $113.88M · Q3 2026
- Remedium Capital Partners, LLC 1.16M sh · $103.33M · Q3 2026
- BRAIDWELL LP 879.47K sh · $78.08M · Q2 2026
- Siren, L.L.C. 868.60K sh · $77.33M · Q3 2026
- Commodore Capital LP 846.79K sh · $75.18M · Q2 2026
More on Artia Global Partners LP
FAQ
How long has Artia Global Partners LP held SYRE?
Artia Global Partners LP has disclosed SYRE holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Artia Global Partners LP's current position in SYRE?
As of Q3 2026, Artia Global Partners LP holds 4.00K shares of SYRE (SPYRE THERAPEUTICS INC), valued at $356.12K, representing 0.07% of its reported portfolio and ranking #49.
Has Artia Global Partners LP been buying or selling SYRE?
In the latest 13F filing (Q3 2026), Artia Global Partners LP held unchanged its position in SYRE. The position peaked in Q3 2026 at 4.00K shares.
Which other funds hold SYRE?
Other major institutional holders of SYRE include Paradigm Biocapital Advisors LP, PERCEPTIVE ADVISORS LLC, RTW INVESTMENTS, LP, among 65 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.